1,390 press releases in English indexed under real estate.
Firm to celebrate investors at The Harvest in Woodinville and unveil a new brand honoring founder Ed Springman BELLEVUE, Wash., Oct. 9, 2026 -- As CES Properties approaches its 57th anniversary, the firm remains a quiet but powerful force in Pacific Northwest real estate,...
TORONTO, October 09, 2026--Primaris Real Estate Investment Trust ("Primaris" or the "Trust") (TSX: PMZ.UN) will be releasing its financial results for the quarter ended September 30, 2026, on Wednesday, October 28, 2026, after the market closes.
GRAND PRAIRIE, Texas, October 09, 2026--Davidson Bogel Real Estate announced today that two Fortune 100 logistics companies have signed leases totaling approximately 13 acres at 4226 E. Main Street in Grand Prairie, Texas. Davidson Bogel represented the landlord, Imperium Capital, in both transactions.
BestRate Mortgage explains how a HELOC on an out-of-state home can fund a Sarasota County second-home down payment and how its payment affects qualifying.
Ardley's AI-powered automated recapture and retention technology will strengthen PLACE's growing platform for lenders and financial institutions BELLINGHAM, Wash., Oct. 9, 2026 -- PLACE, a real estate and financial services technology unicorn, today announced an agreement to...
The article highlights how experience, communication, and local market knowledge help buyers select the right professional to guide their purchase. MOUNTAIN TOP, Pa., Oct. 9, 2026 --What should buyers look for when choosing a real estate agent in Mountain Top, Pennsylvania?...
Round Rock, TX Friday Oct 9, 2026 @ 8:00 AM Central — Episode 94 of the Rock Solid: Round Rock Business Leaders Podcast, titled "Kasey Jorgenson: From Rescue Swimmer to Real Estate Leader," hosted by Bryan Eisenberg, drops October 7, 2026 with a timely conversation about leadership under pressure, AI disruption in housing, and the economics of going independent. Jorgenson, who leads Jorgenson Real Estate in downtown Round Rock, draws a direct line from Navy rescue swimmer training to how his team manages high-stakes transactions, panicked buyers, and a rapidly evolving Williamson County market as 2027 approaches. The conversation moves briskly through several threads listeners can expect: Surviving an 86% attrition pipeline in Navy rescue swimmer school and translating that grit to real estate self-employment. Why Jorgenson left a major national brokerage after more than 15 years to go independent, and why systems and mastery beat headcount growth. How AI, ChatGPT recommendations, spoken-word content, YouTube, and Google Business Profiles are revolutionizing the way buyers connect with agents. Jorgenson Real Estate has introduced a new in-house AI agent three weeks ago, alongside a pro bono program for sellers facing financial hardship. Jorgenson's calm-under-fire ethos surfaces in a story about a buyer who texted that there had been a murder in the front yard of a listing. "All right, well, let's just take a pause. There's no need to freak out. Let's do some information gathering, see what we're actually dealing with," he recalls telling the agent. On perseverance, he is just as direct: "I was terrible at running. And it was perseverance from that, just refusing to quit.Bryan Eisenberg, bestselling author and international keynote speaker, engages Jorgenson Real Estate on the industry's future, highlighting Google's first major search-interface overhaul in 25 years and Perplexity's recent IPO filing. Jorgenson Real Estate asserts that AI models now prioritize spoken word and testimonials, which is why the brokerage already appears in ChatGPT queries throughout Williamson County.. He points to commercial real estate data, MCP connectors, 35-page home reports, and future "Carfax-style" property histories as near-term disruptors, predicting dramatic change inside one to two years. He also credits Round Rock's Dell-era master plan, strong schools, Old Settlers Park, and improvements along I-35 for anchoring the local market, while flagging education funding as the key variable for future home values. His brokerage, he notes, employs roughly 15 agents and is deliberately staying nimble. About Rock Solid: Round Rock Business Leaders Podcast Produced by Round Rock Studio and hosted by bestselling author and international keynote speaker Bryan Eisenberg, Rock Solid spotlights the entrepreneurs, nonprofits, and companies powering Round Rock, Texas. Each episode explores the strategies, stories, and community ties behind the region's most interesting operators. Episode 94 with Kasey Jorgenson is available now wherever podcasts are heard.
AssetBuilt announced nationwide industrial asset and real estate sales for October–November 2026, featuring EV, energy, and processing equipment auctions.
Acquisition adds a company-owned coastal real estate asset to OFA’s asset base and expands its presence in Choshi as the Company evaluates the property for a premium senior living and wellness-oriented concept
"Electric Vehicle Battery Housing Market: Focus on Application, Product, and Country Analysis - Analysis and Forecast, 2026-2035" has been added to ResearchAndMarkets.com's offering.
Hong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential. The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question. On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight. For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization. Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue. From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities. The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible. A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities The core asset underpinning the partnership is MDR-001, which continues to advance through development. In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety. This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages. Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies. For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence. Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank. According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million. These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints. As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone. Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets. According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series. From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets. MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation. In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases. These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities. Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand. MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
Are contractors and property owners looking for reliable steel parts for construction, repairs, or property improvement projects? Does VB Steel provide practical steel solutions through its Chisholm shop.